Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Molecular responses and chromosomal aberrations in patients with polycythemia vera treated with peg-proline-interferon alpha-2b.

American journal of hematology - 1 Apr 2015

Them Nicole C C, Bagienski Klaudia, Berg Tiina, Gisslinger Bettina, Schalling Martin, Chen Doris, Buxhofer-Ausch Veronika, Thaler Josef, Schloegl Ernst, Gastl Guenther A, Wolf Dominik, Strecker Karin, Egle Alexander, Melchardt Thomas, Burgstaller Sonja, Willenbacher Ella, Zagrijtschuk Oleh, Klade Christoph, Greil Richard, Gisslinger Heinz, Kralovics Robert

Abstract excerpt

Fifty-one polycythemia vera (PV) patients were enrolled in the phase I/II clinical study PEGINVERA to receive a new formulation of pegylated interferon alpha (peg-proline-IFNα-2b, AOP2014/P1101). Peg-proline-IFNα-2b treatment led to high response rates on both hematologic and molecular levels. He...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Chromosome Aberrations

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Interferon-alpha

Share to Interferon alpha-2

Share to Janus Kinase 2

Share to Molecular Targeted Therapy

Share to Polycythemia Vera

Share to Polyethylene Glycols

Source

Open in PubMed Open full text

Identifiers

PMID: 25545244
DOI: 10.1002/ajh.23928
PMCID: PMC4657499

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-25545244-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Molecular responses and chromosomal aberrations in patients with polycythemia vera treated with peg-proline-interferon alpha-2b.PMID 25545244Read ↗

Deciphering the complex clonal heterogeneity of polycythemia vera and the response to interferon alphaSemantic proximity Read ↗

Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon α-2a.Semantic proximity Read ↗

The impact of interferon-alpha2 on HLA genes in patients with polycythemia vera and related neoplasms.Semantic proximity Read ↗

Pegylated interferon: the who, why, and howSemantic proximity Read ↗

Characteristics and clinical significance of cytogenetic abnormalities in polycythemia veraSemantic proximity Read ↗

Sustained major molecular response on interferon alpha-2b in two patients with polycythemia vera.Semantic proximity Read ↗

Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera.Semantic proximity Read ↗

Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera.Semantic proximity Read ↗

Identification of genomic aberrations associated with disease transformation by means of high-resolution SNP array analysis in patients with myeloproliferative neoplasm.Semantic proximity Read ↗

Perspectives on interferon-alpha in the treatment of polycythemia vera and related myeloproliferative neoplasms: minimal residual disease and cure?Semantic proximity Read ↗

Interferon-alpha2 treatment of patients with polycythemia vera and related neoplasms favorably impacts deregulation of oxidative stress genes and antioxidative defense mechanisms.Semantic proximity Read ↗

Germline genetic factors influence the outcome of interferon-α therapy in polycythemia vera.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.